ubrogepant

a calcitonin gene-related peptide receptor antagonist (CGRP-RA), for the acute treatment of migraine

Also Known As:

1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-, (6S)- spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide; MK-1602; ubrelvy

Networked: 92 relevant articles (21 outcomes, 42 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - ubrogepant: 92
  - Pyridines: 88
    - ubrogepant: 92

Experts

1.	Dodick, David W: 12 articles (04/2022 - 08/2016)
2.	Lipton, Richard B: 9 articles (04/2022 - 08/2016)
3.	Lu, Kaifeng: 8 articles (01/2022 - 11/2019)
4.	Trugman, Joel M: 8 articles (06/2021 - 11/2019)
5.	Jakate, Abhijeet: 7 articles (04/2021 - 12/2019)
6.	Blumenfeld, Andrew M: 6 articles (01/2022 - 01/2020)
7.	Butler, Matthew: 6 articles (01/2022 - 12/2019)
8.	Goadsby, Peter J: 6 articles (03/2021 - 01/2019)
9.	Boinpally, Ramesh: 5 articles (01/2022 - 01/2020)
10.	Finnegan, Michelle: 5 articles (03/2021 - 11/2019)

Related Diseases

1.	Migraine Disorders (Migraine) 01/01/2021 - "The safety and efficacy of ubrogepant for the acute treatment of a single migraine attack did not differ by the presence of major cardiovascular risk factors. " 04/25/2022 - "A greater proportion of TIRs in the ubrogepant arm vs the placebo arm were satisfied with treatment at 2 (33% vs 21%, P = 0.006) and 24 h (58% vs 28%, P < 0.001) and indicated that their migraine improved at 2 h vs placebo (30% vs 18%, P = 0.006). " 02/26/2021 - "Ubrogepant is effective and safe for the treatment of acute migraine. " 01/01/2020 - "Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials." 01/01/2020 - "Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II."
2.	Pain (Aches) 01/01/2022 - "This was an analysis of pooled efficacy data from the ACHIEVE I and ACHIEVE II phase 3 trials, in which efficacy of ubrogepant was assessed at 2 h after taking study medication for pain freedom, absence of most bothersome symptom (MBS), and pain relief. " 03/01/2022 - "ACHIEVE II trial demonstrated efficacy of ubrogepant 50 mg compared with placebo (2-hour pain freedom: OR = 1.62, 95% CI = 1.14-2.29; 2-hour MBS freedom: OR = 1.65, 95% CI = 1.25-2.20). " 01/28/2021 - "Most studies found that participants receiving Ubrogepant were free from pain within 2 h when compared to placebo. " 08/03/2023 - "For each ubrogepant-treated attack, meaningful pain relief (MPR) and return to normal function (RNF) at 2 and 4 h post-dose over 30 days was assessed. " 01/01/2023 - "No difference was found in the mean percentage of ubrogepant-treated pmM and non-pmM attacks that achieved 2-h pain relief with ubrogepant 50 mg (64.8% [39.9] vs. 65.2% [32.4]; p = 0.683) and with 100 mg (67.1% [37.4] vs. 68.4% [30.2]; p = 0.273). "
3.	Headache (Headaches) 11/15/2023 - "This PRODROME trial was a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial of ubrogepant 100 mg conducted at 75 research centres and headache clinics in the USA. " 04/01/2021 - "Our study confirms and extends the efficacy profile and tolerability of ubrogepant in a real-world tertiary headache clinic and identifies factors that may predict efficacy. " 01/01/2021 - "A real-world study conducted at a tertiary headache center also confirmed the efficacy and safety of ubrogepant. " 11/15/2023 - "Absence of moderate or severe headache within 24 h after a dose occurred after 190 (46%) of 418 qualifying prodrome events that had been treated with ubrogepant and after 121 (29%) of 423 qualifying prodrome events that had been treated with placebo (odds ratio 2·09, 95% CI 1·63-2·69; p<0·0001). " 01/01/2023 - "Of 734 women in the modified intent-to-treat population, 354 reported ≥1 menstrual cycle start date and a ubrogepant-treated headache day in the same month. "
4.	Secondary Headache Disorders 01/01/2020 - "A dose of ubrogepant effective in the medication overuse headache model (100 mg/kg) was then selected to determine if repeated administration would produce latent sensitization. " 01/01/2020 - "Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache." 01/01/2020 - "These studies suggest ubrogepant may offer an effective acute treatment of migraine without risk of medication overuse headache.Trial" 01/01/2020 - "This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repeated oral administration of ubrogepant induces latent sensitization relevant to medication overuse headache in rats. " 01/01/2020 - "Ubrogepant dose-dependently blocked both stress- and nitric oxide donor-induced cephalic and hindpaw allodynia in the sumatriptan-induced medication overuse headache model with a 50% effective dose of ∼50 mg/kg. Unlike sumatriptan, ubrogepant 100 mg/kg in repeated effective doses did not produce cutaneous allodynia or latent sensitization. "
5.	Migraine with Aura (Familial Hemiplegic Migraine) 04/01/2021 - "Predictive factors for being a "good responder" to ubrogepant, defined as headache relief for ≥75% of all treated attacks at 2 hours after taking ubrogepant, included migraine with aura, episodic migraine, <5 prior unsuccessful preventive or acute treatment trials. "

Related Drugs and Biologics

1.	rimegepant sulfate
2.	Calcitonin Gene-Related Peptide Receptor Antagonists
3.	lasmiditan
4.	Calcitonin Gene-Related Peptide
5.	Tryptamines (Triptans)
6.	Serotonin (5 Hydroxytryptamine)
7.	galcanezumab
8.	erenumab
9.	fremanezumab
10.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Therapeutics
3.	Oral Administration
4.	Contraindications
5.	Injections